Table 2 Outcomes from randomization to end of study visit 95% CI: 95% confidence interval; IQR: interquartile range; MVS: mechanical ventilatory support; SD: standard deviation; # total number of events, * All adverse events were non-serious
Outcome | Ivermectin (N = 250) | Placebo (N = 251) | Odds Ratio (95% CI) | p value |
|---|---|---|---|---|
Primary | ||||
Hospitalization, N (%) | 14 (5.60) | 21 (8.37) | 0.65 (0.32–1.31) | 0.227 |
Secondary | ||||
Time to hospitalization days (in those who were hospitalized), median (IQR) | 3.5 (3–5) | 3 (2–5) | – | 0.59 |
Invasive MVS, N (%) | 4 (1.60) | 3 (1.20) | 1.34 (0.30–6.07) | 0.70 |
Time to invasive MVS days (in those who required MVS), mean (±SD) | 5.25 (1.71) | 10 (2) | – | 0.019 |
Negative nasal swab day 3, N (%) | 113 (47.08) | 120 (49.79) | 0.90 (0.63–1.28) | 0.55 |
Negative nasal swab day 12, N (%) | 212 (89.08) | 221 (92.47) | 0.76 (0.45–1.27) | 0.29 |
Dialysis, N (%) | 1 (0.40) | 1 (0.40) | 1.00 (0.06–16.14) | 1 |
All-cause mortality, N (%) | 4 (1.60) | 3 (1.20) | 1.34 (0.30–6.07) | 0.70 |
Safety (adverse events)#, total (%) * | 45 (18.00) | 53 (21.11) | – | 0.6 |